Moore
Laboratory
Molecular Neurodegeneration
The Moore Laboratory investigates the molecular pathophysiology of Parkinson’s disease, a chronic progressive neurodegenerative movement disorder. The majority of Parkinson’s disease cases occur in a sporadic manner although 5 to 10 % of cases are inherited, with causative mutations identified in at least eight genes. The Moore Laboratory studies the normal biology and pathobiology of gene products that cause inherited Parkinson’s disease, including the common leucine-rich repeat kinase 2 (LRRK2, PARK8), the retromer component VPS35 (PARK17), the E3 ubiquitin ligase parkin (PARK2), and the lysosomal P5-type ATPase ATP13A2 (PARK9).
The laboratory’s goal is to elucidate the normal biological function of these proteins in the mammalian brain and the molecular mechanism(s) through which disease-associated variants in these proteins induce neuronal dysfunction and eventual neurodegeneration in inherited forms of Parkinson’s disease. Through a clear understanding of the physiological function and pathological dysfunction of these proteins, the Moore Laboratory hopes to gain important insight into the molecular mechanisms and cellular pathways underlying neurodegeneration in inherited and idiopathic forms of Parkinson’s disease.
The laboratory adopts a translational approach to identify and validate novel therapeutic strategies that may slow or halt progressive neurodegeneration in Parkinson’s disease. To achieve these goals, the lab uses a multidisciplinary approach employing molecular, cellular and biochemical experimental techniques in a number of model systems including human cell lines, primary neuronal cultures, the baker’s yeast Saccharomyces cerevisiae, transgenic, knockout and viral-mediated gene transfer rodent models, and human brain tissue. The Moore Laboratory’s mission is to understand the molecular pathogenesis of Parkinson’s disease in order to develop novel targeted therapies and neuroprotective strategies to treat or prevent this devastating disease.
Join Our Team
We are continually seeking highly motivated individuals with a strong publication record to join our energetic and fast-paced lab as postdoctoral fellows. A Ph.D. with molecular and cellular biology or neuroscience experience is required to apply. Additional experience in biochemistry, proteomics, microscopy, viral vector technology, neuropathology and/or behavioral assays is preferred (but not necessary). Interested candidates should email Dr. Moore to inquire. Graduate students interested in joining the lab are encouraged to apply through Van Andel Institute Graduate School.
Recent News & Press
Learn More
5 areas to watch in Parkinson’s research
University of Minnesota, Van Andel Institute receive two-year, $5.8M grant to study Parkinson’s disease and cellular senescence
After the recent exenatide results, what’s next in Parkinson’s disease research and clinical trials?
Our Impact
We’re raising thousands to save millions.
We’re turning hope into action for the millions of people around the world affected by diseases like cancer and Parkinson’s. Find out how you can help us make a difference.
- 141 peer-reviewed papers published in 2025, 74 of which were in high-impact journals
- 15 VAI-SU2C Epigenetics Dream Team clinical trials launched to date
- 10 clinical trials and related projects supported by VAI through the International Linked Clinical Trials Program
Darren Moore, Ph.D.
Chair and Professor, Department of Neurodegenerative Science; Director, MiND Program; Jay Van Andel Endowed Chair in Parkinson’s Disease Research
Areas of Expertise
Inherited Parkinson’s disease, LRRK2, VPS35, Parkin, ATP13A2, neurodegenerative disease models
Biography
Dr. Moore received a bachelor degree in molecular biology and genetics from the University of East Anglia in 1998 and his Ph.D. in molecular neuroscience from the University of Cambridge in 2001. He conducted postdoctoral research in the Department of Neurology and Udall Parkinson’s Disease Center of Excellence at the Johns Hopkins University School of Medicine. He later joined the Neurology faculty at Johns Hopkins in 2006 as assistant professor, before moving to the Brain Mind Institute of the Swiss Federal Institute of Technology (EPFL) in 2008. In 2014, Dr. Moore was recruited as an associate professor in the newly created Center for Neurodegenerative Science at Van Andel Institute, becoming full professor in 2017. In 2020, he was appointed as chair of the Department of Neurodegenerative Science and, in 2024, as the Jay Van Andel Endowed Chair in Parkinson’s Disease Research. His research focuses on understanding the cell biology and pathophysiological mechanisms underlying familial genes for Parkinson’s, including LRRK2, VPS35, α-synuclein and ATP13A2, and their contributions to the endolysosomal pathway.
Alexis Bergsma, Ph.D.
Senior Lab Manager, Department of Neurodegenerative Science
Xi Chen, Ph.D.
Research Scientist, Department of Neurodegenerative Science
Ashley Douglass, B.S.
Senior Administrative Assistant II, Department of Neurodegenerative Science
Maxwell Frye
Ph.D. Student, VAI Graduate School
Research focus to be determined.
Vanessa Howland
Ph.D. Student, VAI Graduate School
Research Focus: Investigating genes associated with familial Parkinson's disease
Miguel Martinez
Ph.D. Student, VAI Graduate School
Research focus to be determined.
Kayla Sipple
Research Technician, Department of Neurodegenerative Science
Erin Williams, Ph.D.
Program Director, MiND